SRRKScholar Rock Holding Corp

Nasdaq scholarrock.com


$ 15.10 $ 0.14 (0.94 %)    

Thursday, 02-May-2024 15:59:54 EDT
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 15.1
$ 15.15
$ 0.00 x 0
$ 15.11 x 200
$ 14.80 - $ 15.25
$ 5.56 - $ 21.17
675,715
na
1.26B
$ 0.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-19-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-07-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-07-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-09-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-07-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-14-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 03-19-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-reiterates-buy-on-scholar-rock-holding-maintains-20-price-target

Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $20 pr...

 scholar-rock-is-a-potential-ma-target-its-exploration-of-obesity-market-garners-interest-analyst

Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of k...

 raymond-james-initiates-coverage-on-scholar-rock-holding-with-strong-buy-rating-announces-price-target-of-30

Raymond James analyst Gary Nachman initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy rating and ann...

 piper-sandler-maintains-overweight-on-scholar-rock-holding-maintains-28-price-target

Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and maintains $28 price...

 truist-securities-reiterates-buy-on-scholar-rock-holding-maintains-20-price-target

Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $20 pr...

 hc-wainwright--co-reiterates-buy-on-scholar-rock-holding-maintains-30-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 ...

 nio-reports-upbeat-earnings-joins-dave-v2x-riskified-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.

 scholar-rock-presents-new-preclinical-data-demonstrating-potential-benefit-of-srk-439-for-healthy-weight-loss-management

Preclinical findings presented at Keystone Symposia show lean mass preservation, fat mass loss, and improved glucose metabolism...

 scholar-rock-announces-presentation-of-new-preclinical-data-evaluating-srk-439-in-obesity-at-keystone-symposia

SRK-439 is a novel selective myostatin inhibitor designed for the treatment of cardiometabolic disordersPreclinical data suppor...

 scholar-rock-provides-2024-corporate-update-and-priorities

- Advancing industry-leading antimyostatin pipeline, comprised of multiple, novel assets with unparalleled selectivity, to trea...

 scholar-rock-holding-q3-2023-eps-053-misses-052-estimate

Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate o...

 earnings-scheduled-for-november-7-2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

 scholar-rock-presents-new-data-from-phase-1-dragon-trial-showing-anti-tumor-activity-in-anti-pd-1-resistant-metastatic-ccrcc-patients-and-supporting-srk-181-continued-tolerability

Promising anti-tumor activity in heavily pretreated clear cell renal cell carcinoma (ccRCC) patientsObjective response rate (OR...

 why-owens-corning-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed bus...

 general-dynamics-microsoft-waste-management-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks traded lower, with the Nasdaq Composite falling more than 1% on Wednesday. Here are some big stocks recording gains...

 jefferies-upgrades-scholar-rock-holding-to-buy-announces-20-price-target

Jefferies analyst Michael Yee upgrades Scholar Rock Holding (NASDAQ:SRRK) from Hold to Buy and announces $20 price target.

 scholar-rock-to-present-clinical-and-biomarker-data-from-the-phase-1-dragon-trial-at-the-sitc-38th-annual-meeting

Poster presentations to include safety, efficacy, and biomarker data from Part A and B of the DRAGON trial in patients with adv...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION